Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 702 | $427,152,584 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 4 | 911.39 | 3,646 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 6 | 910.47 | 5,463 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 4 | 909.49 | 3,638 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 4 | 906.26 | 3,625 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 2 | 907.54 | 1,815 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 2 | 905.5 | 1,811 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 1 | 904.8 | 905 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 1 | 903.35 | 903 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 1 | 902.66 | 903 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 4 | 901.41 | 3,606 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 5 | 900.45 | 4,502 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 17 | 898.51 | 15,275 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 7 | 899.37 | 6,296 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 9 | 897.68 | 8,079 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 3 | 896.59 | 2,690 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 2 | 895.38 | 1,791 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 5 | 893.16 | 4,466 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 9 | 892.5 | 8,032 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 7 | 891.52 | 6,241 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 2 | 890.75 | 1,782 | D |
03 May 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 May 2024 | Sale | 3 | 889.5 | 2,668 | D |
01 May 2024 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 02 Jan 2024 | Sale | 16,848 | 900 | 15,163,200 | I |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 13 | 965.35 | 12,550 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 16 | 964.45 | 15,431 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 20 | 963.6 | 19,272 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 9 | 962.42 | 8,662 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 14 | 961.59 | 13,462 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 15 | 960.53 | 14,408 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 9 | 959.47 | 8,635 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 2 | 957.78 | 1,916 | D |
03 Apr 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Apr 2024 | Sale | 2 | 958.86 | 1,918 | D |
03 Apr 2024 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Apr 2024 | Sale | 250 | 964.73 | 241,182 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 196 | 968.2 | 189,767 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 17 | 966.3 | 16,427 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 78 | 965.51 | 75,310 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 1 | 962.87 | 963 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 512 | 959.36 | 491,192 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 47 | 961.74 | 45,202 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 730 | 957.35 | 698,866 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 477 | 958.34 | 457,128 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 1,108 | 956.34 | 1,059,625 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 545 | 955.54 | 520,769 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 870 | 954.66 | 830,554 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 576 | 953.77 | 549,372 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 444 | 952.4 | 422,866 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 182 | 951.92 | 173,249 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 988.3 | 988 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 4 | 987.33 | 3,949 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 8 | 986.58 | 7,893 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 10 | 985.76 | 9,858 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 12 | 983.61 | 11,803 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 19 | 984.45 | 18,705 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 11 | 982.67 | 10,809 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 15 | 981.64 | 14,725 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 980.21 | 980 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 979.87 | 980 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 978.09 | 978 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 2 | 976.81 | 1,954 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 2 | 977.27 | 1,955 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 2 | 975.7 | 1,951 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 974.78 | 975 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 2 | 972.29 | 1,945 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 971.75 | 972 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 4 | 970.38 | 3,882 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 969.18 | 969 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 968.66 | 969 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | RYAN ARTHUR F | Director | 01 Mar 2024 | Sale | 1 | 967.5 | 968 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Mar 2024 | Sale | 358 | 967.5 | 346,365 | D |
28 Feb 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | LAROSA JOSEPH J | EVP General Counsel and Secret | 26 Feb 2024 | Sale | 1,000 | 990 | 990,000 | D |
28 Feb 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 26 Feb 2024 | Sale | 500 | 990 | 495,000 | D |
28 Feb 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 26 Feb 2024 | Sale | 500 | 995 | 497,500 | D |
26 Feb 2024 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | BASSLER BONNIE L | Director | 26 Feb 2024 | Sale | 854 | 979.25 | 836,280 | D |
26 Feb 2024 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | LAROSA JOSEPH J | EVP General Counsel and Secret | 22 Feb 2024 | Sale | 1,000 | 967.65 | 967,650 | D |
26 Feb 2024 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 23 Feb 2024 | Sale | 500 | 985 | 492,500 | D |
26 Feb 2024 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 22 Feb 2024 | Sale | 1,000 | 960 | 960,000 | D |
26 Feb 2024 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 22 Feb 2024 | Sale | 1,000 | 965 | 965,000 | D |
26 Feb 2024 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 22 Feb 2024 | Sale | 1,000 | 970 | 970,000 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 200 | 951.77 | 190,354 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 375 | 950.45 | 356,419 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 112 | 949.07 | 106,296 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 150 | 948.7 | 142,305 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 240 | 947.81 | 227,474 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 95 | 945.81 | 89,852 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 620 | 944.3 | 585,466 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 2,691 | 943.51 | 2,538,985 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 275 | 941.41 | 258,888 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 750 | 939.6 | 704,700 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 4,261 | 940.44 | 4,007,215 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 226 | 938.13 | 212,017 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 439 | 937.94 | 411,756 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 09 Feb 2024 | Sale | 500 | 955 | 477,500 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 08 Feb 2024 | Sale | 500 | 945 | 472,500 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 600 | 955 | 573,000 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 1,100 | 954.57 | 1,050,027 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 1,342 | 953.47 | 1,279,557 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 1,046 | 952.62 | 996,441 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 487 | 951.39 | 463,327 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 344 | 950.49 | 326,969 | D |
09 Feb 2024 16:12 | REGN | REGENERON PHARMACEUTICALS Inc | LAROSA JOSEPH J | EVP General Counsel and Secret | 07 Feb 2024 | Sale | 1,000 | 950 | 950,000 | D |
08 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 07 Feb 2024 | Sale | 19 | 953 | 18,107 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)